Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q4 2021 vs. Q3 2021
How the institutions holding Cingulate Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 0 | 5 | +5 |
| Shares | 0 | 1.11M | +1.11M |
| Value | $0 | $3.06M | +$3.06M |
New holders (5)
Institutions that held Cingulate Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 886,254 | $2.45M | 0.61% |
| Lynwood Capital Management Inc. | 125,000 | $345.0K | 0.33% |
| Altium Capital Management LP | 83,931 | $232.0K | 0.07% |
| Susquehanna International Group, LLP | 10,338 | $29.0K | 0.00% |
| UBS Group AG | 4,716 | $13.0K | 0.00% |
Sold out (0)
Institutions that held Cingulate Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
None.